BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

An Open-label Phase IIa, Non-randomized Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy

The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Bone Metastases
• Intervention / Treatment: Drug: Radium-223 chloride (BAY88-8223)

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1000
  • Liège, Belgium, 4000
• Norway
  • Oslo, Norway, 0310
• United Kingdom
  • Sheffield, United Kingdom

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Patient is female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potential the result of a urine human chorionic gonadotropin pregnancy test, performed on the same day as and with the result known before study drug administration, must be negative.
• Histological or cytological evidence of primary breast cancer.
• Bone dominant disease (with or without metastases in soft tissue, lymph nodes and/or skin) with at least one non-irradiated bone metastasis on planar bone scintigraphy/SPECT ± CT within previous the 12 weeks.
• Patient has unequivocally progressed on endocrine therapy and further benefit from endocrine therapy is considered unlikely (progression must be documented based on imaging and/or other clinically relevant information).
• Patient has been on bisphosphonate therapy for at least 3 months prior to treatment start and no change to bisphosphonate therapy is expected during the treatment phase of the study, or patient is not being treated with bisphosphonates, and such treatment is not planned to start during the treatment period.
• Latest endocrine therapy stopped at least 2 weeks prior to treatment start.
• ECOG PS 0 - 2.
• Life expectancy ≥6 months.
• Patient fulfils the following certain laboratory requirements.

Exclusion Criteria:

• Received an investigational drug within 4 weeks prior to the administration of Alpharadin, or is scheduled to receive one during the treatment period.
• Received chemotherapy, immunotherapy, or external beam radiation therapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute ARs as a result of such therapy.
• Is likely to require chemotherapy or immunotherapy within the 16 weeks treatment period.
• Presence of imminent or established spinal cord compression based on clinical findings and/or MRI.
• Presence of other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not breast cancer metastases.
• Presence of unequivocal visceral metastases requiring chemotherapy treatment in the next 6 months, based on Investigator's judgement. Brain metastases are allowed only if well controlled and if not associated with symptoms. Treatment for brain metastasis should have been completed at least 8 weeks prior to treatment start.

• Patients with any other serious illness or medical condition, such as:

  • any uncontrolled infection
  • clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or heart failure more severe than this (NYHA Heart Failure Class III or IV)
  • Crohn's disease or ulcerative colitis
  • Bone marrow myelodysplasia
  • Unmanageable faecal incontinence

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Radium-223 dichloride (Xofigo, BAY 88-8223); Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.	Drug: Radium-223 chloride (BAY88-8223); The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)	16 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Pain	1 year
All safety data, including adverse events, changes in laboratory variables, vitals signs, physical examination, late toxicity	1 year
Biochemical markers (additional bone markers and CA15.3)	16 weeks
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)	1 year

Collaborators and Investigators

• Sponsor: Bayer

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): January 1, 2012

Study Registration Dates

• First Submitted: February 17, 2010
• First Submitted That Met QC Criteria: February 17, 2010
• First Posted (Estimate): February 18, 2010

Study Record Updates

• Last Update Posted (Estimate): June 25, 2014
• Last Update Submitted That Met QC Criteria: June 24, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Radium Ra 223 dichloride
• Other Study ID Numbers: 15468; 2009-012189-30 (EudraCT Number); BC1-09 (Other Identifier: Algeta ASA)